Hi! My name is Anthony Hightower. I was diagnosed with Type 1 Diabetes at age 13 and have spent my adult life seeking to raise awareness, educate, and support research efforts.
As an avid cyclist, I co-founded a team called “Duck Fiabetes” and have leveraged this passion to raise over $60,000 to the American Diabetes Association’s Tour de Cure. I was recently a camp counselor at Camp Hodia, a camp for diabetic youth, where I was camp counselor to 12 teenage boys.
I was born and raised in Northern California. I own and operate an industrial Shrink wrap business. In my free time I love talking about Diabetes hanging out with family, friends, and my fur babies (Chelsie and Brady).
If every there was a rock star diabetes drug, Afrezza is it.
In this episode Corinna Cornejo speaks with Emily Coles about how the inhalable insulin Afrezza has captured the imagination of the diabetes patient community and its impact on the diabetes treatment landscape.
We also share highlights from a live interview with Sam Finta, aka AfrezzaUser. Sam spent years being as careful as possible and feeling like “giving up” on his diabetes. Severe depression and anxiety inspired him to seek better means of diabetes treatment. He was fortunate to obtain one of the last openings in MannKind’s Afrezza drug trial in Atlanta through Dr. Bruce Bode of the Atlanta Diabetes Center. Since then, Sam has provided honest, genuine, and truthful information about his experiences with Afrezza via social media ( on Yahoo message Boards, blogspots and others) .
You can find the complete interview with Sam Finta in our archives.
Dana Lewis is one of the creators of the DIY Pancreas System, or DIYPS.
In this episode Corinna Cornejo and Mila Ferrer talk about the promise and perils DYIPS represents.
Diagnosed at age 14 with type 1, Dana Lewis had the usual experience of years of frustration of dealing with diabetes devices that did not communicate with each other. She often imagined a system that would take data from each device, run it through the algorithm that every person with diabetes uses in their head dozens (or hundreds) of times a day, and automate some of the decision-making process. In late 2013, this became a reality after someone shared their code to help pull data off of a CGM in real-time. Dana and her now-husband Scott Leibrand used the CGM data to create a decision-assist system they called #DIYPS, the “Do-It-Yourself Pancreas System”.
We share highlights from Emily Cole’s interview with Dana Lewis in this podcast. You can find the complete interview in the TuDiabetes archives..
Locemia Solutions is a Canadian-based pharmaceutical development company, which sole focus is on innovating the rescue treatment of severe hypoglycemia. The team at Locemia is working on providing people with diabetes and those that touch their lives, with a simple, needle-free glucagon rescue product for the treatment of severe hypoglycemia, which would be easy to teach, easy to carry and easy to use – helping to expand the number of people who feel confident in dealing with the unpredictability of hypoglycemia, and providing peace of mind for people who use insulin every day. Locemia’s passion and promise – driven by its members personal involvement and investment in the diabetes community – is to fill an unmet need through innovation, awareness and empowerment—rooted in needle-free simplicity, for everyone to be able to help anyone—quickly and easily— deal with severe low blood sugar.
Sam Finta, aka AfrezzaUser, spent years being as careful as possible and feeling like “giving up” on his diabetes. Severe depression and anxiety inspired him to seek better means of diabetes treatment, and he was fortunate to obtain one of the last openings in MannKind’s Afrezza drug trial in Atlanta through Dr. Bruce Bode of the Atlanta Diabetes Center.
Immediately and from day one, Sam’s felt his life was changed for the better. Since then, he has done his best through social media (Yahoo message Boards, blogspots and others) to provide honest, genuine and truthful information about his experience with Afrezza. He credits it with saving his life and giving him hope as he wait with countless other people with diabetes to have a near “normal” life again. This is what started Sam’s desire to reach other people with diabetes with his firsthand knowledge of Afrezza.
Todd Hobbs, MD, is chief medical officer (CMO) for Novo Nordisk in North America. In this role, Dr. Hobbs focuses on the implications of diabetes for the company and for patients, for healthcare professionals and for healthcare systems. He provides medical guidance and input to the clinical development and life cycle management strategies for diabetes and obesity-related projects, as well as input into the R&D pipeline and participate in consultant advisory boards.
Dr. Hobbs began his career at Novo Nordisk in 2004 as a Field Medical Scientific Director. In 2010, he moved to the in-house position of Senior Medical Director of Diabetes. Prior to being named North American CMO, he led Medical Affairs activities for all insulin products and devices at Novo Nordisk, including strategy and tactical activities in support of current and future products.
Dr. Hobbs is a physician with a clinical focus in Diabetes. After internship and residency, he established his clinical practice focusing on the intensive management of patients of all ages with diabetes. During his 10 year clinical career based in Louisville, Kentucky, he cared for more than 2,500 adults and children with diabetes, including outpatient, inpatient and intensive care patients. During his clinical practice, he also served as Chairman of the Medicine Department for Baptist Hospital Medical Center in Kentucky.
“At Novo Nordisk, we are intensely focused on the patient experience and are committed to finding solutions to help those living with diabetes achieve their goals,” said Anne Phillips, MD, senior vice president, clinical medical & regulatory affairs for Novo Nordisk. “As a patient and parent of a child living with diabetes, Todd brings a unique perspective and shares our passion for patient centricity.”
His personal dedication to the treatment of diabetes began nearly 25 years ago when he was diagnosed with type 1 diabetes and intensified with the diagnosis of one of his sons with the same condition at the age of 5.
Prometheon Pharma launched it’s #NoPricks campaign in order to help bring it’s needle-free insulin delivery patch to market. Here’s their mission statement:
At Prometheon, we foresee persons with diabetes no longer needing to inject themselves daily with insulin. We envision vaccines that will not spoil in hot climates and can be administered easily, painlessly, and inexpensively to impoverished children in developing countries. We imagine once-weekly drug patches for mental health disorders and chronic diseases that maximize adherence to prescribed therapy by greatly simplifying drug regimens. We dream of fields and streams absent of medical waste because biodegradable products and manufacturing processes are created to protect the fragile ecosystems on our planet. Above all, we believe advances in drug delivery and new drug discovery can be made accessible to everyone in the world. At Prometheon, we are devoted to our mission and promise to advance global health equity and improve human existence through the pursuit and translation of scientific discovery.
Merith Basey, MSc
Merith’s introduction to global public health and Type 1 diabetes was via AYUDA in Quito, Ecuador, following her postgraduate studies on Latin America at La Universidad Complutense in Madrid. She went on to serve as AYUDA’s first Country Officer in Ecuador, later joining the headquarters in Washington DC as Global Program Director, where she was responsible for growing AYUDA’s country programs and strengthening local capacity in Ecuador, Bolivia, Dominican Republic and Belize.
Since 2012, Merith has also worked closely with the diabetes community in Haiti initially in support of the first diabetes education camp for young people with Type 1 diabetes. She is continually seeking ways to help strengthen the work of AYUDA’s partner FHADIMAC (www.fhadimac.org) on the ground.
As a result of almost a decade of witnessing the reality that many children and their families still do not have consistent access to insulin and other diabetes supplies, and disheartened by the lack of global action towards this; Merith and a small team of advocates with experience in diabetes communities in resource poor settings came together to launch the 100 Campaign, with the support of the International Insulin Foundation.
About the Campaign
The International Insulin Foundation (IIF) has been active in the area of Type 1 diabetes in the developing world for 10 years. On World Diabetes Day (November 14th) 2012, the IIF launched the “100 Campaign” with the goal of achieving 100% access to insulin by 2022, the 100th anniversary of insulin use to treat a person with Type 1 diabetes.
Access to Insulin:
While barriers to insulin access are most prominent in resource-poor countries, barriers also exist in other parts of the world. In developing countries the cost of insulin can consume as much as 25% of a family’s income. In the USA some uninsured individuals ration their insulin to save money, and end up in emergency rooms or with avoidable diabetes-related complications. The 100 Campaign was started as a means to address these and other issues related to barriers to insulin access.
Follow us at: facebook/100Campaign
@100Campaign_esp (in Spanish)
This presentation will provide an overview of:
Patient barriers to insulin therapy
Clinician barriers to insulin therapy
Solutions for overcoming the barriers
A review of injection therapy
Mark has over 26 years of medical device experience in both marketing and engineering. Prior to joining Asante, Mark was the Director of Marketing for Advanced Bionics — a Boston Scientific Company. While there, he brought to market the company’s first commercially available implantable spinal cord stimulator for the treatment of chronic pain. Prior to Advanced Bionics, Mark was the Director of Marketing for Medtronic MiniMed. There, he helped develop and launch the Paradigm insulin pump and also helped to integrate Continuous Glucose Monitoring technology into the pump. Before Medtronic MiniMed, Mark worked his way up from Design Engineer to Senior Market Manager at Respironics. To date, he holds over 35 medical device patents. Mark earned his B.S. in Mechanical Engineering and MSIA from Carnegie Mellon University.
John has completed the worlds longest cross-country ski race, the largest organised bicycle race in the world, New York half-marathon and multiple triathlons. He uses Humalog and Lantus disposable insulin pens to treat his diabetes with four daily injections of insulin and has great control over his blood sugar levels.